score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Clinical evidence			Copy Number	EGFR	Amplification				0.0	0.0		Putatively Actionable	Gefitinib	EGFR inhibition	Targeted therapy	Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.	Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829-37.	https://doi.org/10.1200/JCO.2005.01.0793													0				EGFR Amplification	1.0	KIRP-A4-7734	TCGA-A4-7734-01	
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.S1254R	0.5843	89.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881													0	1002.0	0.6707	1.0	MET p.S1254R (Missense)	0.0	KIRP-A4-7734	KIRP-A4-7734-TP	KIRP-A4-7734-NB
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 3	version 2	0.373						Investigate Actionability	Platinum	Platinum-based chemotherapy	Chemotherapy	Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.	Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.	https://doi.org/10.1038/ncomms9683													0				COSMIC Signature (version 2) 3 (37%)		KIRP-A4-7734		
Biologically Relevant				Rearrangement	JAK1	Fusion	RP4-535B20.1--JAK1			0.0	0.0																					0				RP4-535B20.1--JAK1 Fusion		KIRP-A4-7734		
Biologically Relevant				Copy Number	PMS2	Amplification				0.0	0.0																					0				PMS2 Amplification		KIRP-A4-7734	TCGA-A4-7734-01	
Biologically Relevant				Microsatellite Stability	Supporting variants		PMS2 Amplification, RP4-535B20.1--JAK1 Fusion, PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PMS2 Amplification, RP4-535B20.1--JAK1 Fusion, PRDM2 p.703_704insP (Insertion)		KIRP-A4-7734		
Biologically Relevant				Mutational Signature	COSMIC Signature 20	version 2	0.297																									0				COSMIC Signature (version 2) 20 (30%)		KIRP-A4-7734		
